|
Delayed
OTC Markets
10:00:08 2026-08-24 EDT
|
5-day change | 1st Jan Change | ||
| 15.75 USD | -3.26% |
|
-.--% | +162.50% |
| 02:18am | French and Benelux stocks-Factors to watch on September 15 | RE |
| 12:53am | France's Genfit Plans Phase 2a Trial of Liver Failure Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 45.63B | |||||
| 43.96B | - | - | - | - | - |
| 43.73B | |||||
| 40.23B | |||||
| 31.86B |
- Stock Market
- Stocks
- GNFT Stock
- GNFTF Stock
- Charts GENFIT
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
